001     120027
005     20240228135008.0
024 7 _ |a 10.1038/ng.2950
|2 doi
024 7 _ |a pmid:24705250
|2 pmid
024 7 _ |a pmc:PMC4282994
|2 pmc
024 7 _ |a 1061-4036
|2 ISSN
024 7 _ |a 1546-1718
|2 ISSN
024 7 _ |a altmetric:2264557
|2 altmetric
037 _ _ |a DKFZ-2017-00615
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Fontebasso, Adam M
|b 0
245 _ _ |a Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.
260 _ _ |a New York, NY
|c 2014
|b Nature America
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1490702300_15176
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Pediatric midline high-grade astrocytomas (mHGAs) are incurable with few treatment targets identified. Most tumors harbor mutations encoding p.Lys27Met in histone H3 variants. In 40 treatment-naive mHGAs, 39 analyzed by whole-exome sequencing, we find additional somatic mutations specific to tumor location. Gain-of-function mutations in ACVR1 occur in tumors of the pons in conjunction with histone H3.1 p.Lys27Met substitution, whereas FGFR1 mutations or fusions occur in thalamic tumors associated with histone H3.3 p.Lys27Met substitution. Hyperactivation of the bone morphogenetic protein (BMP)-ACVR1 developmental pathway in mHGAs harboring ACVR1 mutations led to increased levels of phosphorylated SMAD1, SMAD5 and SMAD8 and upregulation of BMP downstream early-response genes in tumor cells. Global DNA methylation profiles were significantly associated with the p.Lys27Met alteration, regardless of the mutant histone H3 variant and irrespective of tumor location, supporting the role of this substitution in driving the epigenetic phenotype. This work considerably expands the number of potential treatment targets and further justifies pretreatment biopsy in pediatric mHGA as a means to orient therapeutic efforts in this disease.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Bone Morphogenetic Proteins
|2 NLM Chemicals
650 _ 7 |a Smad Proteins
|2 NLM Chemicals
650 _ 7 |a ACVR1 protein, human
|0 EC 2.7.11.30
|2 NLM Chemicals
650 _ 7 |a Activin Receptors, Type I
|0 EC 2.7.11.30
|2 NLM Chemicals
700 1 _ |a Papillon-Cavanagh, Simon
|b 1
700 1 _ |a Schwartzentruber, Jeremy
|b 2
700 1 _ |a Nikbakht, Hamid
|b 3
700 1 _ |a Gerges, Noha
|b 4
700 1 _ |a Fiset, Pierre-Olivier
|b 5
700 1 _ |a Bechet, Denise
|b 6
700 1 _ |a Faury, Damien
|b 7
700 1 _ |a De Jay, Nicolas
|b 8
700 1 _ |a Ramkissoon, Lori A
|b 9
700 1 _ |a Corcoran, Aoife
|b 10
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 11
|u dkfz
700 1 _ |a Sturm, Dominik
|0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
|b 12
|u dkfz
700 1 _ |a Johann, Pascal
|0 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8
|b 13
|u dkfz
700 1 _ |a Tomita, Tadanori
|b 14
700 1 _ |a Goldman, Stewart
|b 15
700 1 _ |a Nagib, Mahmoud
|b 16
700 1 _ |a Bendel, Anne
|b 17
700 1 _ |a Goumnerova, Liliana
|b 18
700 1 _ |a Bowers, Daniel C
|b 19
700 1 _ |a Leonard, Jeffrey R
|b 20
700 1 _ |a Rubin, Joshua B
|b 21
700 1 _ |a Alden, Tord
|b 22
700 1 _ |a Browd, Samuel
|b 23
700 1 _ |a Geyer, J Russell
|b 24
700 1 _ |a Leary, Sarah
|b 25
700 1 _ |a Jallo, George
|b 26
700 1 _ |a Cohen, Kenneth
|b 27
700 1 _ |a Gupta, Nalin
|b 28
700 1 _ |a Prados, Michael D
|b 29
700 1 _ |a Carret, Anne-Sophie
|b 30
700 1 _ |a Ellezam, Benjamin
|b 31
700 1 _ |a Crevier, Louis
|b 32
700 1 _ |a Klekner, Almos
|b 33
700 1 _ |a Bognar, Laszlo
|b 34
700 1 _ |a Hauser, Peter
|b 35
700 1 _ |a Garami, Miklos
|b 36
700 1 _ |a Myseros, John
|b 37
700 1 _ |a Dong, Zhifeng
|b 38
700 1 _ |a Siegel, Peter M
|0 0000-0002-5568-6586
|b 39
700 1 _ |a Malkin, Hayley
|b 40
700 1 _ |a Ligon, Azra H
|b 41
700 1 _ |a Albrecht, Steffen
|b 42
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 43
|u dkfz
700 1 _ |a Ligon, Keith L
|b 44
700 1 _ |a Majewski, Jacek
|b 45
700 1 _ |a Jabado, Nada
|b 46
700 1 _ |a Kieran, Mark W
|b 47
773 _ _ |a 10.1038/ng.2950
|g Vol. 46, no. 5, p. 462 - 466
|0 PERI:(DE-600)1494946-5
|n 5
|p 462 - 466
|t Nature genetics
|v 46
|y 2014
|x 1546-1718
909 C O |o oai:inrepo02.dkfz.de:120027
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 43
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT GENET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b NAT GENET : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21